News | November 20, 2009

New Blood Thinner Ends Trial With Mixed Results

November 18, 2009 — A new, reversible blood thinner did not prove superior over placebo for its primary endpoints of heart attack and need for revascularization, but it did reduce in-stent blood clots. Researchers reported the findings in a late-breaking clinical trial presentation at the American Heart Association’s Scientific Sessions this week.

CHAMPION PLATFORM, a phase III trial, included 5,362 angioplasty-plus-stent patients randomized to receive either a placebo or the investigational drug cangrelor during procedures to reopen coronary artery blockages. Cangrelor is a potent, fast-acting and reversible anti-clotting drug delivered intravenously.

After their procedures, all patients received 600 mg of the oral, nonreversible anti-platelet drug clopidogrel, which is routinely used in such procedures.

The trial, which enrolled patients beginning in 2006, ended when an interim review committee concluded that cangrelor would fail to show superiority over clopidogrel for its primary endpoint: a composite of all-cause death, heart attack and the need for coronary revascularization procedures.

“There was no statistically significant difference between the two arms of the trial at our 48-hour endpoint,” said Deepak L. Bhatt, M.D., MPH, chief of cardiology at the VA Boston Healthcare System. “However, a number of secondary endpoints had very interesting and informative findings. For instance, all-cause death as a stand-alone endpoint was reduced significantly from 0.7 percent in controls to 0.2 percent (67 percent reduction) in the cangrelor group.

“It is intriguing, of course, but it is a secondary endpoint and needs to be interpreted with some caution given that the primary endpoint was not met and the number of deaths overall was low,” he said.

Furthermore, acute stent thrombosis was significantly reduced in the test group.

“That’s something that interventional cardiologists really worry about, because stent thrombosis is often associated with a recurrent heart attack or death,” said Dr. Bhatt, who is also director of the integrated interventional cardiovascular program at Brigham and Women’s Hospital and the VA Boston Healthcare System, and a faculty member at Harvard Medical School in Boston. “Acute stent thrombosis was reduced from 0.6 percent in controls to 0.2 percent in the test group (69 percent reduction), again a significant benefit. So there seems to be a plausible mechanism by which mortality may have been reduced since stent thrombosis was reduced.”

Researchers found no difference in endpoints between test and control groups for severe bleeding and need for blood transfusion. However, less severe bleeding was significantly higher with the new agent, 5.4 percent vs. 3.4 percent in controls, an indication of the investigational drug’s potency, Dr. Bhatt said. Because it is reversible and is delivered through an intravenous line, bleeding events can be ended quickly after the drug is no longer administered.

Clopidogrel is given orally and is irreversible - once it binds to a platelet it remains for the life of that blood cell, usually seven to 10 days. That puts clopidogrel patients at higher risk of bleeding complications if they need emergency surgery, he said.

“At least in theory, cangrelor has all the attributes that an interventional cardiologist would want: Its onset of action is very quick and it’s very potent, but on the back end you can turn it off,” Dr. Bhatt said.

For more information: www.americanheart.org, www.themedicinescompany.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init